Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma

Por Martinez-Lopez, J, Sanchez-Vega, B, Barrio, S, Cuenca, I, Ruiz-Heredia, Y, Alonso, R, Rapado, I, Marin, C, Cedena, M-T, Paiva, B, Puig, N, Mateos, M-V, Ayala, R, Hernández, M-T, Jimenez, C, Rosiñol, L, Martínez, R, Teruel, A-I, Gutiérrez, N, Martin-Ramos, M-L, Oriol, A, Bargay, J, Bladé, J, San-Miguel, J, Garcia-Sanz, R, Lahuerta, J-J
Publicado no Leukemia (2017)